Lai C C, Miller E C, Miller J A, Liem A
McArdle Laboratory for Cancer Research, University of Wisconsin Medical School, Madison 53706.
Carcinogenesis. 1988 Jul;9(7):1295-302. doi: 10.1093/carcin/9.7.1295.
Deacetylation of N-hydroxy-2-acetylaminofluorene (N-hydroxy-AAF) to N-hydroxy-2-aminofluorene (N-hydroxy-AF) has been proposed as one of the critical metabolic steps in the formation of hepatic DNA adducts and the initiation of liver tumors in 12-day-old male B6C3F1 mice. In this study, the importance of the microsomal deacetylase activity for N-hydroxy-AAF in the initiation of hepatocarcinogenesis in these mice was demonstrated by using a carboxylesterase and amidase inhibitor, bis(p-nitrophenyl)phosphate (BNPP), that is much less toxic in vivo than is paraoxon. Pre-incubation of liver microsomes from 12-day-old male B6C3F1 mice with 10(-3) M BNPP reduced the deacetylase activity by 80% while paraoxon inhibited the deacetylase activity completely at a concentration of 10(-4) M. Pretreatment of 12-day-old male B6C3F1 mice with 4 X 75 micrograms doses of BNPP/g body weight before the administration of N-hydroxy-AAF reduced the hepatic N-(dGuo-8-yl)-AF adduct levels to 1.09 and 0.68 pmol/mg DNA compared with 2.87 and 1.64 pmol/mg DNA for mice treated once with 0.06 or 0.03 mumol of N-hydroxy-AAF/g body weight respectively. However, BNPP pretreatments did not affect the levels of the acetylated DNA adducts, N-(dGuo-8-yl)-AAF and 3-(dGuo-N2-yl)-AAF, formed by these doses of N-hydroxy-AAF. The initiation of liver tumors by N-hydroxy-AAF was also inhibited by BNPP pretreatment. Thus, for mice that received single doses of 0.12, 0.06 and 0.03 mumol of N-hydroxy-AAF/g body weight, the multiplicities of liver tumors at 10 months were reduced by BNPP pretreatments to 5.6, 1.0 and 0.3 compared with multiplicities of 11.8, 4.8 and 1.7 without pretreatment respectively. On the other hand, BNPP pretreatments had no significant inhibitory effects on the levels of the hepatic DNA-N-(dGuo-8-yl)-AF adduct or on the liver tumor multiplicities induced by comparable doses of N-hydroxy-AF. It is concluded that deacetylation of N-hydroxy-AAF to N-hydroxy-AF is essential for the metabolic activation, DNA-N-(dGuo-8-yl)-AF adduct formation and liver tumor initiation in infant male B6C3F1 mice by N-hydroxy-AAF.
N-羟基-2-乙酰氨基芴(N-hydroxy-AAF)脱乙酰化为N-羟基-2-氨基芴(N-hydroxy-AF)被认为是12日龄雄性B6C3F1小鼠肝脏DNA加合物形成及肝肿瘤起始过程中的关键代谢步骤之一。在本研究中,通过使用羧酸酯酶和酰胺酶抑制剂双(对硝基苯基)磷酸酯(BNPP),证明了微粒体脱乙酰酶活性对N-hydroxy-AAF在这些小鼠肝癌发生起始过程中的重要性,BNPP在体内的毒性远低于对氧磷。将12日龄雄性B6C3F1小鼠的肝脏微粒体与10⁻³ M BNPP预孵育,可使脱乙酰酶活性降低80%,而对氧磷在10⁻⁴ M浓度时可完全抑制脱乙酰酶活性。在给予N-hydroxy-AAF之前,用4×75微克/克体重剂量的BNPP预处理12日龄雄性B6C3F1小鼠,可使肝脏N-(dGuo-8-yl)-AF加合物水平降至1.09和0.68皮摩尔/毫克DNA,而分别用0.06或0.03微摩尔/克体重的N-hydroxy-AAF单次处理的小鼠,其加合物水平分别为2.87和1.64皮摩尔/毫克DNA。然而,BNPP预处理并不影响这些剂量的N-hydroxy-AAF形成的乙酰化DNA加合物N-(dGuo-8-yl)-AAF和3-(dGuo-N2-yl)-AAF的水平。BNPP预处理也抑制了N-hydroxy-AAF引发的肝肿瘤。因此,对于接受单次0.12、0.06和0.03微摩尔/克体重N-hydroxy-AAF的小鼠,10个月时肝肿瘤的数量经BNPP预处理后分别降至5.6、1.0和0.3,而未预处理时分别为11.8、4.8和1.7。另一方面,BNPP预处理对肝脏DNA-N-(dGuo-8-yl)-AF加合物水平或由相当剂量的N-hydroxy-AF诱导的肝肿瘤数量没有显著抑制作用。结论是,N-hydroxy-AAF脱乙酰化为N-hydroxy-AF对于N-hydroxy-AAF在幼年雄性B6C3F1小鼠中的代谢活化、DNA-N-(dGuo-8-yl)-AF加合物形成及肝肿瘤起始至关重要。